Compare SHC & LNTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SHC | LNTH |
|---|---|---|
| Founded | 2015 | 1956 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.5B | 3.8B |
| IPO Year | 2020 | 2015 |
| Metric | SHC | LNTH |
|---|---|---|
| Price | $17.51 | $58.47 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 6 |
| Target Price | $17.80 | ★ $74.17 |
| AVG Volume (30 Days) | ★ 3.3M | 1.3M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | 0.20 | ★ 2.39 |
| Revenue | $1,150,379,000.00 | ★ $1,525,933,000.00 |
| Revenue This Year | $6.23 | N/A |
| Revenue Next Year | $5.99 | $1.98 |
| P/E Ratio | $89.49 | ★ $24.60 |
| Revenue Growth | ★ 2.67 | 1.95 |
| 52 Week Low | $9.53 | $47.25 |
| 52 Week High | $17.78 | $111.29 |
| Indicator | SHC | LNTH |
|---|---|---|
| Relative Strength Index (RSI) | 67.06 | 60.27 |
| Support Level | $14.96 | $51.84 |
| Resistance Level | $16.48 | $59.30 |
| Average True Range (ATR) | 0.48 | 2.10 |
| MACD | 0.20 | 0.63 |
| Stochastic Oscillator | 91.94 | 89.94 |
Sotera Health Co provides sterilization, analytical lab testing, and advisory services to help ensure that medical, pharmaceutical and food products are safe for healthcare practitioners, patients, and consumers. The company operates in three segments: Sterigenics, Nordion, and Nelson Labs. Sterigenics provides outsourced terminal sterilization and irradiation services for medical device, pharmaceutical, food safety, and applications; Nordion provides Co-60 and gamma irradiators, which are the key components to the gamma sterilization process; and Nelson Labs provides outsourced microbiological and analytical chemistry testing for the medical device and pharmaceutical industries. Its geographical segments are the United States, Canada, Europe and other regions.
Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its products are in three categories: Precision Diagnostics, Radiopharmaceutical Oncology, and Strategic Partnerships and Other Revenue. Precision Diagnostic products assist healthcare professionals Find and Follow diseases, with a focus in cardiology. Radiopharmaceutical Oncology diagnostics and therapeutics help HCPs Find, Fight and Follow cancer. Strategic Partnerships focus on enabling precision medicine through the use of biomarkers, digital solutions and pharma services platforms, and also includes license of RELISTOR to Bausch Health Companies, Inc.